Table 3.
Cox proportional mortality hazard for women with CKD prescribed bisphosphonate therapy by cardiovascular event status
| Model | No Prior CV Event | Prior CV Event | P Value for Interaction (Bisphosphonate and Prior CV Event) | ||
|---|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | ||
| Approach 1 | |||||
| Crude | 0.97 (0.85 to 1.12) | 0.71 | 1.17 (1.01 to 1.36) | 0.04 | 0.07 |
| Adjusteda | 0.90 (0.78 to 1.04) | 0.15 | 1.22 (1.04 to 1.42) | 0.01 | 0.004 |
| Approach 2 | |||||
| Crude | 1.01 (0.83 to 1.24) | 0.89 | 1.15 (0.93 to 1.43) | 0.21 | 0.40 |
| Adjusteda | 0.95 (0.78 to 1.17) | 0.65 | 1.25 (1.01 to 1.57) | 0.05 | 0.07 |
| Approach 3 | |||||
| Crude | 1.27 (1.02 to 1.58) | 0.03 | 1.33 (1.05 to 1.68) | 0.02 | 0.78 |
| Adjustedb | 1.21 (0.97 to 1.51) | 0.09 | 1.48 (1.16 to 1.88) | 0.001 | 0.22 |
| Approach 4 | |||||
| Crude | 0.93 (0.70 to 1.23) | 0.60 | 0.85 (0.64 to 1.13) | 0.26 | 0.65 |
| Adjustedc | 0.55 (0.37 to 0.82) | 0.003 | 0.94 (0.66 to 1.34) | 0.73 | 0.05 |
CV, cardiovascular; HR, hazard ratio; 95% CI, 95% confidence interval.
Adjusted for age; smoking status; prior CV event (myocardial infarction, hospitalization for congestive heart failure, or stroke); history of cardiac dysrhythmia, atherosclerotic coronary artery disease, diabetes, or chronic obstructive pulmonary disease; HMG-CoA reductase inhibitor prescription; body mass index; systolic BP; and baseline eGFR, serum albumin, urine protein excretion, and LDL and HDL cholesterol.
Adjusted for the above covariates (with the exception of LDL cholesterol), prescription for β-blocker or aspirin, and history of a dual-energy x-ray absorptiometry (DEXA) scan in the year before index date.
Propensity score-adjusted approach. The propensity score was derived from the following variables: age, body mass index, height, systolic and diastolic BP, glucocorticoid therapy at any time during the 12 months before the index date, HMG-CoA reductase inhibitor prescription, β-blocker prescription, clopidogrel prescription, aspirin use, history of smoking, hyper- or hypothyroidism, osteopenia, osteoporosis, diabetes, history of prior cardiovascular event, eGFR, LDL and HDL cholesterol, serum albumin, proteinuria, DEXA study in the prior 3 years, number of visits with primary care physician in the prior 12 months, referral to a rheumatologist in the prior 12 months, and number of visits with a rheumatologist in the prior 12 months.